McKesson Corporation, listed on the New York Stock Exchange as MCK, recently experienced a series of adjustments in its stock ratings from various financial analysts. The updates reflect a mix of confidence and caution regarding the company’s market performance.
On November 25, 2025, analysts at Weiss Ratings reaffirmed their “buy (a-)” rating for McKesson, a positive signal for investors. In contrast, the same day, Zacks Research downgraded the company’s rating from “strong-buy” to “hold.” This contrasting feedback highlights the differing perspectives on McKesson’s future potential.
Earlier in November, Weiss Ratings upgraded McKesson from a “buy (b+)” to a “buy (a-)” rating, further indicating some optimism in the market. The same day, Evercore ISI reaffirmed their “outperform” rating with a price target of $1,000.00, suggesting strong confidence in the stock’s growth potential.
In a notable shift, Wells Fargo & Company raised their price target for McKesson from $816.00 to $914.00, adjusting their rating to “equal weight.” This adjustment marks a significant increase in expectations for the stock’s performance. Similarly, UBS Group AG raised its target from $920.00 to $980.00, maintaining a “buy” rating.
On the other hand, Morgan Stanley increased its price target from $857.00 to $916.00, while also assigning an “overweight” rating to the stock. These changes indicate that some analysts remain bullish on McKesson’s prospects despite recent downgrades.
McKesson also announced a quarterly dividend of $0.82 per share, which is set to be paid on January 2, 2026. Shareholders of record by December 1, 2025, will be eligible for this dividend. This annualizes to $3.28 and represents a yield of 0.4%, with a payout ratio of 10.21%.
In related news, Napoleon B. Rutledge, Jr., the Chief Accounting Officer, sold 329 shares of McKesson stock on November 7, 2025, at an average price of $861.63, totaling approximately $283,476.27. Following this transaction, Rutledge holds 328 shares, valued at around $282,614.64, reflecting a significant decrease of 50.08% in his position. The transaction was disclosed in a filing with the Securities and Exchange Commission.
McKesson Corporation operates in the healthcare sector, providing services both in the United States and internationally. The company functions through four primary segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment is responsible for distributing a range of pharmaceutical products, including branded, generic, and specialty drugs.
As the market adjusts its outlook on McKesson, investors will be closely monitoring these ratings and the forthcoming dividend as indicators of the company’s financial health and market position.
